Back

Novo Nordisk CEO urges FDA oversight of untested peptides

Verifying
  • Mike Doustdar called for FDA oversight of untested peptides sold through underground markets.
  • Novo Nordisk shares fell 17% over the past year, versus Eli Lilly's 57% gain.
  • Robert Kennedy Jr. initiated a policy pivot involving roughly 14 popular peptides.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.
Novo Nordisk CEO urges FDA oversight of untested peptides - CoinPost Terminal